PART I . Overview We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation ofour novel Drug Response Predictor (DRP) platform. TheDRP technology is designed to define the gene expression signatures in cancer cells that predict the cancer cells sensitivity to a specific cancer therapeutic. Once defined, the DRP gene expression signature can then be assessed i...
Q2 FY2026 — expected 2026-09-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001437749-26-010310 | EDGAR | 94K words |
| 2025-03-31 | 2024-12-31 | 0001437749-25-010198 | EDGAR | — |
| 2024-03-08 | 2023-12-31 | 0001213900-24-020864 | EDGAR | — |
| 2023-03-13 | 2022-12-31 | 0001213900-23-019295 | EDGAR | — |
| 2022-05-17 | 2021-12-31 | 0001213900-22-027311 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001437749-25-035003 | EDGAR | 18K words |
| 2025-08-15 | 2025-06-30 | 0001437749-25-027146 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001437749-25-015780 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001437749-24-035314 | EDGAR | — |
| 2024-08-05 | 2024-06-30 | 0001213900-24-065252 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001213900-24-042997 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001213900-23-086382 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001213900-23-066893 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001213900-23-038609 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001213900-22-072355 | EDGAR | — |
| 2022-10-07 | 2022-06-30 | 0001213900-22-062840 | EDGAR | — |
| 2022-05-27 | 2022-03-31 | 0001213900-22-030179 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-01 | 0001213900-26-038061 | EDGAR | 4K words |
| 2026-03-09 | 0001213900-26-024952 | EDGAR | — |
| 2026-03-06 | 0001213900-26-024339 | EDGAR | — |
| 2026-02-19 | 0001213900-26-018161 | EDGAR | — |
| 2026-02-04 | 0001213900-26-011826 | EDGAR | — |
| 2026-01-29 | 0001213900-26-009157 | EDGAR | — |
| 2025-12-23 | 0001213900-25-124935 | EDGAR | — |
| 2025-12-08 | 0001213900-25-118989 | EDGAR | — |
| 2025-09-24 | 0001213900-25-090872 | EDGAR | — |
| 2025-09-22 | 0001213900-25-090197 | EDGAR | — |
211 total filings indexed. 184 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001860657 |
| Ticker | ALLR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.allarity.com |
| Listed | 2021-12-21 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ALLR (~200 tokens, structured JSON with cryptographic provenance)